Leaderboards/Lung Cancer Treatments and Mutations

Lung Cancer Treatments and Mutations

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
J. Duan
Shanxi Medical University
2
Shun Lu
Shanghai Chest Hospital
3
Christopher Abbosh
Cancer Research UK
4
Adam H. Fox
Medical University of South Carolina
5
Miranda Gogishvili
Medical Technologies (Czechia)
6
Maise Al Bakir
The Francis Crick Institute
7
Erica C. Nakajima
AstraZeneca (Netherlands)
8
Ning Li
Sun Yat-sen University
9
Jialin Zhou
Shandong First Medical University
10
Diana Romero
The Nature Conservancy

Papers

1
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLC
New England Journal of Medicine|2024
295 cit.
2
Publication in Cancer Epidemiology (2024) [270 citations, W4404337253]
Cancer Epidemiology|2024
270 cit.
3
Publication in Nature (2025) [25 citations, W4407722099]
Nature|2025
25 cit.
4
Pulmonologists’ Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer
CHEST Journal|2024
8 cit.
5
The American Cancer Society National Lung Cancer Roundtable strategic plan: Advancing comprehensive biomarker testing in non–small cell lung cancer
Cancer|2024
8 cit.
6
Tumor Size Is Not Everything: Advancing Radiomics as a Precision Medicine Biomarker in Oncology Drug Development and Clinical Care. A Report of a Multidisciplinary Workshop Coordinated by the RECIST Working Group
JCO Precision Oncology|2024
6 cit.
7
Adjuvant icotinib for resected EGFR-mutated stage II–IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study
Signal Transduction and Targeted Therapy|2025
4 cit.
8
Navigating treatment combinations in small-cell lung cancer
Nature Medicine|2024
3 cit.
9
Publication in CA A Cancer Journal for Clinicians (2026) [3 citations, W7135055018]
CA A Cancer Journal for Clinicians|2026
3 cit.
10
Publication in Heliyon (2024) [2 citations, W4402047723]
Heliyon|2024
2 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
Lee A. Albacker
Foundation Medicine (United States)
2
Mark M. Awad
Memorial Sloan Kettering Cancer Center
3
Dineika Chandrananda
University of Cambridge
4
Elizabeth Moore
University of Cambridge
5
Anna Piskorz
Cancer Research UK Cambridge Center
6
Aaron N. Hata
Harvard University
7
Wen‐Zhao Zhong
Guangdong Academy of Medical Sciences
8
John A. Demchok
National Cancer Institute
9
Danila Seidel
University Hospital Cologne
10
Shankha Satpathy
Broad Institute

Papers

1
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
JAMA Oncology|2022
384 cit.
2
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer
Cancer Cell|2022
222 cit.
3
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Nature|2023
145 cit.
4
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer
Journal of Clinical Oncology|2024
123 cit.
5
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Journal of Thoracic Oncology|2023
91 cit.
6
Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
Signal Transduction and Targeted Therapy|2023
77 cit.
7
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer
Nature Cancer|2022
69 cit.
8
Stitchr: stitching coding TCR nucleotide sequences from V/J/CDR3 information
Nucleic Acids Research|2022
47 cit.
9
Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer
Annals of Oncology|2024
47 cit.
10
Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
Journal of Thoracic Oncology|2023
42 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Pasi A. Jänne
Harvard University
2
Matthew Meyerson
Broad Institute
3
Harold Varmus
Memorial Sloan Kettering Cancer Center
4
Jeffrey A. Engelman
Cancer Research Center
5
Daniel A. Haber
Howard Hughes Medical Institute
6
Masahiro Fukuoka
National Institute of Standards and Technology
7
Timothy A. Chan
Cleveland Clinic
8
Bruce E. Johnson
Harvard University
9
Yi‐Long Wu
Guangdong Academy of Medical Sciences
10
Alice T. Shaw
Dana-Farber Cancer Institute

Papers

1
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
New England Journal of Medicine|2004
11.5k cit.
2
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Science|2004
9.4k cit.
3
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
New England Journal of Medicine|2009
8.2k cit.
4
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science|2015
7.9k cit.
5
A New Initiative on Precision Medicine
New England Journal of Medicine|2015
5.2k cit.
6
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Science|2007
4.5k cit.
7
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
New England Journal of Medicine|2014
4.4k cit.
8
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Proceedings of the National Academy of Sciences|2004
4.3k cit.
9
The landscape of somatic copy-number alteration across human cancers
Nature|2010
4.1k cit.
10
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
The Lancet Oncology|2009
4.1k cit.

Reagents for Lung Cancer Treatments and Mutations

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

PromegaEvidence 62

VEGF Bioassay

Cited in 36 papers
#G719A
View Evidence →

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 64

SynGAP (D88G1) Rabbit Monoclonal Antibody

Cited in 30 papers
#9479$161,351
View Evidence →
Cell Signaling TechnologyEvidence 60

Phospho-Rev-erb alpha (Ser55/59) Antibody

Cited in 25 papers
#2129$362
View Evidence →
Cell Signaling TechnologyEvidence 66

XPC (D1M5Y) Rabbit Monoclonal Antibody

Cited in 24 papers
#14768$161,351
View Evidence →

🌟 All-Time

Most validated

PromegaEvidence 62

VEGF Bioassay

Cited in 36 papers
#G719A
View Evidence →
Cell Signaling Technology

ZHX2 Antibody

Cited in 35 papers
#20937$317
View Evidence →
Cell Signaling TechnologyEvidence 67

COL3A1 Antibody

Cited in 30 papers
#30565$317
View Evidence →